MOPC315 plasmacytoma [9], was employed. Upon processing, the U3'' L chain yields a CDR3-fragment comprising residues 91-101. This Id-peptide is presented on the I-Ed class 11 molecule. Amino acids Phe94, Arg9', of the
CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells
✍ Scribed by Jan Alvar Lindencrona; Susanne Preiss; Thomas Kammertoens; Thomas Schüler; Marie Piechocki; Wei-Zen Wei; Barbara Seliger; Thomas Blankenstein; Rolf Kiessling
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- French
- Weight
- 134 KB
- Volume
- 109
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
HER‐2/neu (HER‐2) is a cell surface proto‐oncogene that is often overexpressed in carcinomas. Passive administration of anti‐HER‐2 antibodies in breast cancer patients has achieved promising results, but less is known about the role of antibodies in active immunization. We asked whether B cells/antibodies are needed for tumor immunity induced by plasmid (HER‐2 and GM‐CSF) immunization. HER‐2 specific tumor immunity relied completely on both CD4^+^ and CD8^+^ T cells. IFN‐γ, and to a lesser extent IL‐4, seemed to be crucial cytokines during tumor rejection. Protection was associated with production of anti‐HER‐2 IgG antibodies in B cell competent mice. After immunization, however, B cell‐deficient mice rejected HER‐2‐expressing tumors as efficiently as control littermates. We conclude that T cells are the main effector cells in DNA vaccine induced immunity against HER‐2 and that anti HER‐2 antibodies are not necessary to elicit a protective anti tumor immune response in this model. © 2003 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract The development of autochtonous mammary tumors in __HER‐2/neu__ transgenic mice is facilitated by immune tolerance to the __neu‐__transgene. However, appropriate vaccination strategies can initiate immune system‐mediated antitumor response by a process that requires IFN‐γ. We investigat